One of the top stories to catch my eye this week has triggered a discussion on whether recommendations for screening should be adjusted. And it has nothing to do with mammography.

Hypofractionated radiation therapy (RT) has become an intriguing treatment option for cancer thanks to its shortened therapy schedule relative to conventional RT. A recently presented analysis has shown it also largely matches up with conventional RT on cure rates and side effects when used for low-risk prostate cancer.

A steroidal pain-management treatment used during radiation therapy for bone metastases has made good on its earlier promise, meaningfully outperforming placebo in a double-blind, randomized phase 3 trial. 

Mevion Medical Systems is expanding its collaboration with Washington University in St. Louis to study Mevion’s HYPERSCAN pencil beam scanning technology and its effects on the delivery of intensity modulated proton therapy (IMPT) treatment delivery.

iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, will present updated clinical data, host in-booth clinician presentations and showcase the latest in radiation technology at the American Society for Radiation Oncology (ASTRO) meeting in San Antonio, TX from October 18-21, 2015.

Retroactively implementing ACR’s 2014 LungRADS classification criteria, an academic medical center increased the positive predictive value in a CT lung-screening cohort of more than 1,600 patients by a factor of 2.5—without driving an increase in surgeries following false negatives.

Eli Lilly and Company (NYSE: LLY) and ImaginAb Inc. are pleased to announce a preclinical research collaboration to study potential novel T cell-based immuno-oncology therapies.

They sparkle on your jewelry, but researchers in Australia are investigating whether they can make diamonds that also light up on MRI in order to help spot cancers.